Pierre Falardeau
Chairman at Folia Biotech, Inc.
Profile
Pierre Falardeau is currently the Chairman of Folia Biotech, Inc. and a Director at EVAH Corp.
He previously served as the President & Chief Executive Officer of Ecopia BioSciences, Inc., Verlyx Pharma, Inc., and Thallion Pharmaceuticals, Inc. He also held the position of Vice President-Scientific Affairs at Æterna Zentaris, Inc. Dr. Falardeau earned a doctorate degree from Université Laval in 1987.
Pierre Falardeau active positions
| Companies | Position | Start |
|---|---|---|
Folia Biotech, Inc.
 Folia Biotech, Inc. Drugstore ChainsRetail Trade FOLIA BIOTECH, Inc. operates as a clinical stage biopharmaceutical company. The firm focuses on exploiting its proprietary immuno-therapeutic platform to bring to market efficacious therapeutic products that fulfill large unmet needs principally in oncology and certain infectious diseases. The company was founded by Denis Leclerc in 2006 and is headquartered in Quebec, Canada. | Chairman | 2013-12-31 |
EVAH Corp.
 EVAH Corp. Information Technology ServicesTechnology Services EVAH Corp. develops animal health technologies. The Canadian company was founded in 2020 by Michel Fortin and Nicole Blanchard. Michel Fortin has been the CEO since 2020. | Director/Board Member | - |
Former positions of Pierre Falardeau
| Companies | Position | End |
|---|---|---|
| THALLION PHARMACEUTICALS INC. | Chief Operating Officer | 2009-06-11 |
Ecopia BioSciences, Inc.
 Ecopia BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Ecopia is finding novel anticancer therapies from soil-dwelling micro organisms that are as of this day one of the most prolific sources of these drugs. Their current focus is ECO-4601, a new small molecule that crosses the blood brain barrier and is effective in significantly inhibiting primary tumor growth in the brain. Just like well-known chemotherapies such as doxorubicin and daunorubicin, ECO-4601 comes from microorganisms that live in common soil. ECO-4601 represents a new chemical class that is the fruit of a very unique drug discovery platform called the Decipher® technology | Chief Executive Officer | 2006-12-31 |
| AETERNA ZENTARIS INC. | Chief Tech/Sci/R&D Officer | 2001-12-31 |
Verlyx Pharma, Inc.
 Verlyx Pharma, Inc. Pharmaceuticals: MajorHealth Technology Verlyx Pharma, Inc. develops cancer treatments. It is a pharmaceutical company involved in the development of liver-targeting therapeutic agents for the treatment of liver diseases. The firm’s product VLX103, is a proprietary form of pentamidine that combines hepatoselective and hepatoprotective properties. The company was founded in 1999 by Terry Chow and David Griller and is headquartered in Montréal, Canada. | Chief Executive Officer | - |
Training of Pierre Falardeau
| Université Laval | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| AETERNA ZENTARIS INC. | Health Technology |
| Private companies | 5 |
|---|---|
Ecopia BioSciences, Inc.
Ecopia BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Ecopia is finding novel anticancer therapies from soil-dwelling micro organisms that are as of this day one of the most prolific sources of these drugs. Their current focus is ECO-4601, a new small molecule that crosses the blood brain barrier and is effective in significantly inhibiting primary tumor growth in the brain. Just like well-known chemotherapies such as doxorubicin and daunorubicin, ECO-4601 comes from microorganisms that live in common soil. ECO-4601 represents a new chemical class that is the fruit of a very unique drug discovery platform called the Decipher® technology | Health Technology |
Thallion Pharmaceuticals, Inc.
 Thallion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thallion Pharmaceuticals, Inc. is a biotechnology company focused on developing new pharmaceutical products in the areas of infectious disease and oncology. Its products are Shigamabs, a dual antibody product for the treatment of Shigatoxin-producing E. coli bacterial infections and TLN-4601, a proprietary first in class small molecule with potential efficacy in multiple oncology indications. The company was founded in January 1998 and is headquartered in Dorval, Canada. | Health Technology |
Folia Biotech, Inc.
Folia Biotech, Inc. Drugstore ChainsRetail Trade FOLIA BIOTECH, Inc. operates as a clinical stage biopharmaceutical company. The firm focuses on exploiting its proprietary immuno-therapeutic platform to bring to market efficacious therapeutic products that fulfill large unmet needs principally in oncology and certain infectious diseases. The company was founded by Denis Leclerc in 2006 and is headquartered in Quebec, Canada. | Retail Trade |
Verlyx Pharma, Inc.
Verlyx Pharma, Inc. Pharmaceuticals: MajorHealth Technology Verlyx Pharma, Inc. develops cancer treatments. It is a pharmaceutical company involved in the development of liver-targeting therapeutic agents for the treatment of liver diseases. The firm’s product VLX103, is a proprietary form of pentamidine that combines hepatoselective and hepatoprotective properties. The company was founded in 1999 by Terry Chow and David Griller and is headquartered in Montréal, Canada. | Health Technology |
EVAH Corp.
EVAH Corp. Information Technology ServicesTechnology Services EVAH Corp. develops animal health technologies. The Canadian company was founded in 2020 by Michel Fortin and Nicole Blanchard. Michel Fortin has been the CEO since 2020. | Technology Services |
- Stock Market
- Insiders
- Pierre Falardeau